Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 3/20 | 0.34 |
| ▸ | F10 | P00742 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5330244 | 0.92 | GLA (0.36) | GLAMAPTTP53KDM4EMEN1 | |
| SCHEMBL5330237 | 0.91 | GLA (0.36) | GLAMAPTTP53KDM4EMEN1 | |
| SCHEMBL5329273 | 0.77 | F10 (0.57) | TP53F10 | |
| SCHEMBL5327044 | 0.73 | CNR1 (0.40) | CNR1 | |
| SCHEMBL5326100 | 0.68 | F10 (0.58) | F10 | |
| SCHEMBL5287809 | 0.67 | PDCD1 (0.44) | GLAMAPTTP53KDM4E | |
| SCHEMBL5090992 | 0.64 | F10 (0.61) | F10 | |
| SCHEMBL5324672 | 0.64 | F10 (0.64) | F10 | |
| SCHEMBL4897352 | 0.64 | DRD2 (0.47) | KDM4EMEN1KMT2ALMNAPOLB | |
| Hydrochloric Acid SCHEMBL5322543 | 0.63 | F10 (0.63) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007008144-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AS INHIBITORS OF FACTOR XA | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |